Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Aoki M, Hayashi H, Yedidi RS, Martyr CD, Takamatsu Y, Aoki-Ogata H, Nakamura T, Nakata H, Das D, Yamagata Y, Ghosh AK, Mitsuya H. Aoki M, et al. Among authors: mitsuya h. J Virol. 2015 Nov 18;90(5):2180-94. doi: 10.1128/JVI.01829-15. J Virol. 2015. PMID: 26581995 Free PMC article.
Challenges in the therapy of HIV infection.
Yarchoan R, Mitsuya H, Broder S. Yarchoan R, et al. Among authors: mitsuya h. Immunol Today. 1993 Jun;14(6):303-9. doi: 10.1016/0167-5699(93)90050-U. Immunol Today. 1993. PMID: 8397771 Review.
Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
Humphrey RW, Ohagen A, Davis DA, Fukazawa T, Hayashi H, Höglund S, Mitsuya H, Yarchoan R. Humphrey RW, et al. Among authors: mitsuya h. Antimicrob Agents Chemother. 1997 May;41(5):1017-23. doi: 10.1128/AAC.41.5.1017. Antimicrob Agents Chemother. 1997. PMID: 9145862 Free PMC article.
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Humphrey RW, Wyvill KM, Nguyen BY, Shay LE, Kohler DR, Steinberg SM, Ueno T, Fukasawa T, Shintani M, Hayashi H, Mitsuya H, Yarchoan R. Humphrey RW, et al. Among authors: mitsuya h. Antiviral Res. 1999 Feb;41(1):21-33. doi: 10.1016/s0166-3542(98)00058-8. Antiviral Res. 1999. PMID: 10321576 Clinical Trial.
716 results